

Jan. 15, 1967

# NEWS RELEASE

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL SCHOOL AT DALLAS



FRANK CHAPPELL *Director of Medical Information*

BOB FENLEY *Science News Editor*

DALLAS -- Dr. Max Tishler, president of Merck Sharp & Dohme Research Laboratories Division, will be the Robert A. Welch Foundation Lecturer at The University of Texas Southwestern Medical School at Dallas at 8 p.m. Thursday, March 4, Dr. Charles C. Sprague, Southwestern dean, announced today.

Dr. Tishler, an internationally known research chemist, will speak on the subject of "Drug Discovery and the Chemist."

The Robert A. Welch Foundation of Houston, Tex., instituted the lectureship program to bring outstanding scientists to educational institutions in Texas. Under this program, 74 distinguished chemists have given a total of 213 lectures at 31 institutions in Texas.

Dr. Tishler will also lecture at Rice University in Houston and at St. Mary's University in San Antonio during his week in Texas. The lectureship is arranged by Dr. W. O. Milligan, the Foundation's director of research.

-more-

first add tishler

Dr. Tishler heads the \$57 million-a-year research program of Merck & Co., Inc. He has contributed significantly to research and development in the fields of antibiotics, steroids and vitamins as well as in other fields of medicinal chemistry, having achieved more than 100 patents and published more than 100 papers. Major discoveries made in the Merck Sharp & Dohme Research Laboratories since Dr. Tishler assumed leadership in 1956 include drugs for the treatment of heart disease, hypertension, rheumatoid arthritis and other inflammatory diseases, and mental depression, and animal health products for control of economically significant diseases of poultry and livestock.

A native of Boston, Dr. Tishler received his Ph.D. in chemistry from Harvard University, where he also served as teaching fellow, research associate and instructor in chemistry prior to joining Merck in 1937 as a research chemist.

Dr. Tishler is active in educational affairs and serves on a number of scientific advisory committees affiliated with the U.S. Government, with numerous professional societies of which he is a member, and with the pharmaceutical industry.

January 15, 1969